Westmount Partners LLC Sells 2,890 Shares of Johnson & Johnson $JNJ

Westmount Partners LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 22.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 9,914 shares of the company’s stock after selling 2,890 shares during the quarter. Westmount Partners LLC’s holdings in Johnson & Johnson were worth $1,844,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. CCLA Investment Management raised its stake in Johnson & Johnson by 4.5% during the third quarter. CCLA Investment Management now owns 27,320 shares of the company’s stock valued at $5,064,000 after purchasing an additional 1,174 shares in the last quarter. Cherrydale Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 22.0% in the 3rd quarter. Cherrydale Wealth Management LLC now owns 1,908 shares of the company’s stock worth $354,000 after buying an additional 344 shares during the last quarter. Spartan Planning & Wealth Management purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $858,000. Salvus Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 5.5% in the 3rd quarter. Salvus Wealth Management LLC now owns 7,864 shares of the company’s stock valued at $1,458,000 after acquiring an additional 412 shares during the last quarter. Finally, Diversified Enterprises LLC grew its position in Johnson & Johnson by 1.7% in the third quarter. Diversified Enterprises LLC now owns 9,944 shares of the company’s stock worth $1,844,000 after acquiring an additional 164 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Citigroup upped their price objective on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. HSBC restated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Argus set a $210.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $210.25.

Key Stores Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands the drug’s addressable market and marks the first IL‑23 inhibitor cleared for a pediatric indication, supporting growth expectations. JNJ’s Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
• Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially boosting uptake versus IV dosing — a near-term commercial positive. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
• Positive Sentiment: Multiple analyst pieces and model portfolios highlight JNJ as a high‑yield/defensive S&P 500 holding for 2026, reinforcing investor interest for income-focused portfolios. Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026
• Neutral Sentiment: Preview pieces flag the upcoming quarterly report as a potential catalyst — investors will watch guidance, medical-device trends and pharma growth. What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
• Neutral Sentiment: An article asks whether the recent rally still leaves JNJ undervalued, signaling some analysts see upside if legal exposure stabilizes. Is Johnson & Johnson’s (JNJ) Recent Rally Still Leaving the Stock Undervalued?
• Neutral Sentiment: Disclosure: Rep. Thomas Kean sold up to $100k of JNJ stock — a routine insider sale that may draw attention but isn’t a company operational signal. Rep. Thomas Kean Has Sold Up to $100K Worth Of Johnson & Johnson Stock: Here’s What You Should Know
• Negative Sentiment: A Baltimore jury ordered J&J to pay about $1.5–$1.56 billion in a talc/asbestos mesothelioma case — the largest single‑plaintiff award in the company’s talc litigation history, increasing near‑term legal uncertainty and downside risk. J&J plans to appeal. J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award
• Negative Sentiment: Widespread coverage (Benzinga/Blockonomi/NYPost/MSN) amplifies the headline risk from the talc verdict, which could pressure the stock until legal exposure is resolved or provisioning is clarified. Johnson & Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim

Johnson & Johnson Stock Down 0.8%

NYSE:JNJ opened at $205.72 on Wednesday. The company has a market cap of $495.64 billion, a price-to-earnings ratio of 19.86, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $198.72 and a 200-day simple moving average of $180.11.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.